BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 31851823)

  • 1. Interaction Energetics and Druggability of the Protein-Protein Interaction between Kelch-like ECH-Associated Protein 1 (KEAP1) and Nuclear Factor Erythroid 2 Like 2 (Nrf2).
    Zhong M; Lynch A; Muellers SN; Jehle S; Luo L; Hall DR; Iwase R; Carolan JP; Egbert M; Wakefield A; Streu K; Harvey CM; Ortet PC; Kozakov D; Vajda S; Allen KN; Whitty A
    Biochemistry; 2020 Feb; 59(4):563-581. PubMed ID: 31851823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
    Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
    J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel inhibitors of Keap1/Nrf2 by a promising method combining protein-protein interaction-oriented library and machine learning.
    Shimizu Y; Yonezawa T; Sakamoto J; Furuya T; Osawa M; Ikeda K
    Sci Rep; 2021 Apr; 11(1):7420. PubMed ID: 33795749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors.
    Mou Y; Wen S; Li YX; Gao XX; Zhang X; Jiang ZY
    Eur J Med Chem; 2020 Sep; 202():112532. PubMed ID: 32668381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening approaches for the identification of Nrf2-Keap1 protein-protein interaction inhibitors targeting hot spot residues.
    Asano W; Hantani R; Uhara T; Debaene F; Nomura A; Yamaguchi K; Adachi T; Otake K; Harada K; Hantani Y
    SLAS Discov; 2024 Mar; 29(2):100125. PubMed ID: 37935317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.
    Davies TG; Wixted WE; Coyle JE; Griffiths-Jones C; Hearn K; McMenamin R; Norton D; Rich SJ; Richardson C; Saxty G; Willems HM; Woolford AJ; Cottom JE; Kou JP; Yonchuk JG; Feldser HG; Sanchez Y; Foley JP; Bolognese BJ; Logan G; Podolin PL; Yan H; Callahan JF; Heightman TD; Kerns JK
    J Med Chem; 2016 Apr; 59(8):3991-4006. PubMed ID: 27031670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay for the Inhibition of Keap1-Nrf2 Protein-Protein Interaction.
    Lee S; Abed DA; Beamer LJ; Hu L
    SLAS Discov; 2021 Jan; 26(1):100-112. PubMed ID: 32564647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
    Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
    Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds.
    Pallesen JS; Narayanan D; Tran KT; Solbak SMØ; Marseglia G; Sørensen LME; Høj LJ; Munafò F; Carmona RMC; Garcia AD; Desu HL; Brambilla R; Johansen TN; Popowicz GM; Sattler M; Gajhede M; Bach A
    J Med Chem; 2021 Apr; 64(8):4623-4661. PubMed ID: 33818106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of novel small-molecule NRF2 activators: Structural and biochemical validation of stereospecific KEAP1 binding.
    Huerta C; Jiang X; Trevino I; Bender CF; Ferguson DA; Probst B; Swinger KK; Stoll VS; Thomas PJ; Dulubova I; Visnick M; Wigley WC
    Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2537-2552. PubMed ID: 27474998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replacement of a Naphthalene Scaffold in Kelch-like ECH-Associated Protein 1 (KEAP1)/Nuclear Factor (Erythroid-derived 2)-like 2 (NRF2) Inhibitors.
    Richardson BG; Jain AD; Potteti HR; Lazzara PR; David BP; Tamatam CR; Choma E; Skowron K; Dye K; Siddiqui Z; Wang YT; Krunic A; Reddy SP; Moore TW
    J Med Chem; 2018 Sep; 61(17):8029-8047. PubMed ID: 30122040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kelch-like ECH-associated protein 1 (KEAP1) differentially regulates nuclear factor erythroid-2-related factors 1 and 2 (NRF1 and NRF2).
    Tian W; Rojo de la Vega M; Schmidlin CJ; Ooi A; Zhang DD
    J Biol Chem; 2018 Feb; 293(6):2029-2040. PubMed ID: 29255090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1.
    Unni S; Deshmukh P; Krishnappa G; Kommu P; Padmanabhan B
    FEBS J; 2021 Mar; 288(5):1599-1613. PubMed ID: 32672401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
    Pallesen JS; Tran KT; Bach A
    J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Activity and Structure-Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1/NRF2) Protein-Protein Interaction.
    Heightman TD; Callahan JF; Chiarparin E; Coyle JE; Griffiths-Jones C; Lakdawala AS; McMenamin R; Mortenson PN; Norton D; Peakman TM; Rich SJ; Richardson C; Rumsey WL; Sanchez Y; Saxty G; Willems HMG; Wolfe L; Woolford AJ; Wu Z; Yan H; Kerns JK; Davies TG
    J Med Chem; 2019 May; 62(9):4683-4702. PubMed ID: 30973731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic molecular dynamics approach to the study of peptide Keap1-Nrf2 protein-protein interaction inhibitors and its application to p62 peptides.
    Lu MC; Yuan ZW; Jiang YL; Chen ZY; You QD; Jiang ZY
    Mol Biosyst; 2016 Apr; 12(4):1378-87. PubMed ID: 26935067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of Molecular Details of Keap1-Nrf2 Inhibitors Using Molecular Dynamics and Umbrella Sampling Techniques.
    Londhe AM; Gadhe CG; Lim SM; Pae AN
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31726716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and mechanistic insights into the Keap1-Nrf2 system as a route to drug discovery.
    Madden SK; Itzhaki LS
    Biochim Biophys Acta Proteins Proteom; 2020 Jul; 1868(7):140405. PubMed ID: 32120017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis for the disruption of Keap1-Nrf2 interaction via Hinge & Latch mechanism.
    Horie Y; Suzuki T; Inoue J; Iso T; Wells G; Moore TW; Mizushima T; Dinkova-Kostova AT; Kasai T; Kamei T; Koshiba S; Yamamoto M
    Commun Biol; 2021 May; 4(1):576. PubMed ID: 33990683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions.
    Jiang ZY; Lu MC; You QD
    J Med Chem; 2016 Dec; 59(24):10837-10858. PubMed ID: 27690435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.